Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

This study is a prospective, multicenter, randomized, phase II clinical trial enrolling patients with resectable locally advanced gastric or gastroesophageal junction adenocarcinoma. The study aims to compare the efficacy and safety of perioperative chemotherapy combined with low-dose radiotherapy and tislelizumab versus perioperative chemotherapy alone in this patient population.

NCT Number	NCT07408609
Lead Sponsor	Jiangsu Cancer Institute & Hospital
Conditions	Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment	114 participants
Start Date	2026-02-26
Primary Completion	2029-02-20 (estimated)
Study Completion	2031-02-20 (estimated)
Updated on ClinicalTrials.gov	2026-02-13